Synakis

Synakis has created a vitreous substitute to transform the treatment of retinal detachment and similar conditions which use vitreous substitutes.

Synakis

We patented a biodegradable hydrogel vitreous substitute that is injectable, non-cytotoxic in vitro and in vivo, low-swelling, stable, and optically transparent with a refractive index and density similar to those of the native vitreous.

 

Team Members

Alex Baker
CEO

Molly Shoichet
CSO